within Pharmacolibrary.Drugs.D_Dermatologicals.D10A_AntiAcnePreparationsForTopicalUse.D10AF02_Erythromycin;

model Erythromycin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.35,
    Cl = 3.888888888888889e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.04,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011666666666666665,
    Tlag = 15.0,
    Vdp = 0.02,
    k12 = 6.11111111111111e-06,
    k21 = 6.11111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Erythromycin</td></tr><tr><td>ATC code:</td><td>D10AF02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Erythromycin is a macrolide antibiotic used to treat various bacterial infections, especially in individuals allergic to penicillins. It is effective against respiratory tract, skin, and soft tissue infections and is still approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Bizjak, ED, &amp; Mauro, VF (1997). Digoxin-macrolide drug interaction. <i>The Annals of pharmacotherapy</i> 31(9) 1077–1079. DOI:<a href=\"https://doi.org/10.1177/106002809703100918\">10.1177/106002809703100918</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9296249/\">https://pubmed.ncbi.nlm.nih.gov/9296249</a></p></li><li><p>Yu, KS, et al., &amp; Shin, SG (2001). Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. <i>Clinical pharmacology and therapeutics</i> 70(3) 228–236. DOI:<a href=\"https://doi.org/10.1067/mcp.2001.117703\">10.1067/mcp.2001.117703</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11557910/\">https://pubmed.ncbi.nlm.nih.gov/11557910</a></p></li><li><p>Hall, KW, et al., &amp; DiSanto, AR (1982). Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. <i>Journal of clinical pharmacology</i> 22(7) 321–325. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1982.tb02682.x\">10.1002/j.1552-4604.1982.tb02682.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7107981/\">https://pubmed.ncbi.nlm.nih.gov/7107981</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D10AF02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Erythromycin;
